By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Head Office
Technologielaan 3
Leuven    B - 3001  Belgium
Phone: 32-16-39-60-60 Fax: 32-16-39-60-70



Company News
TiGenix's Phase III Trial Design For Cx601 Endorsed By President-Elect Of ECCO 2/23/2015 7:18:15 AM
TiGenix And Lonza Group Ltd. (LZAGY.PK) Sign Agreement For The Manufacture Of Stem Cell-Based Treatment Of Complex Perianal Fistulas In Crohn's Disease 2/12/2015 7:32:55 AM
TiGenix Participates In Key Conferences In The First Half Of 2015 2/2/2015 9:03:11 AM
European Patent Office Issues Key Patent To TiGenix For Expanded Adipose-Derived Stem Cell Compositions 1/22/2015 7:40:09 AM
TiGenix Submits Its Pivotal US Trial Design For Cx601 To The FDA For Special Protocol Assessment 12/22/2014 7:15:29 AM
TiGenix Starts Phase I Trial Of Cx611 In Severe Sepsis 12/10/2014 8:26:38 AM
TiGenix Completes Patient Recruitment For The European Phase 3 Trial Of Cx601 Ahead Of Schedule 11/12/2014 9:00:30 AM
TiGenix Business And Financial Update For The Third Quarter Of 2014 11/4/2014 10:06:02 AM
TiGenix Publishes Transparency Notification Pursuant To Article 14 Of The Law Of May 2, 2007 10/17/2014 2:11:12 PM
TiGenix To Participate Or Present At Key Conferences In The Second Half Of 2014 9/15/2014 7:51:33 AM